Kymera snags $30 mln Series A
Cambridge, Massachusetts-based Kymera Therapeutics LLC, a biotech company focused on treating previously untreatable diseases, has secured $30 million in Series A financing. Atlas Venture led the round with participation from Lilly Ventures and Amgen Ventures.
30 October 2017•1 min read
